Golub supports fertility company buyout

The New York-based lending firm is backing the acquisition of sperm bank California Cryobank by two healthcare-focused private equity firms.

Golub Capital is providing a one-loan debt facility to support the acquisition of California Cryobank, a sperm bank and cellular therapy company in Los Angeles, by two private equity groups. Golub acted as the sole lead arranger and administrative agent in the transaction. The firm is not disclosing the size of the loan, but has confirmed that it will be providing all of the debt in this deal, which goes toward supporting the acquisition of the fertility company by Longitude Venture Partners II and NovaQuest Pharma Opportunities Fund III, two private equity sponsor funds focused on the healthcare industry.  

Cryobank has built a strong, global presence in both fertility and cellular therapy, said a statement from Golub. “With its leading market position, differentiated value proposition, and best-in-class leadership team, CCB is well-positioned to capitalize on the attractive growth opportunities within reproductive tissue donor services and storage and stem cell banking,” Jonathan Pearl, principal at Golub Capital, said in a news release. “We are excited to support the Company’s growth and partner again with Longitude and NovaQuest and the management team at CCB.” 

Golub provides financing solutions to the middle market, including one-loan financings (through the firm's proprietary MiniGOLD, GOLD, and MegaGOLD facilities), senior secured debt, second lien and subordinated debt, preferred stock and co-investment equity. The firm underwrites and syndicates senior credit facilities up to $300 million. Golub Capital's hold sizes range up to $200 million per transaction. The firm now has $10 billion in capital under management and operates out of New York and Chicago. 

For an in-depth interview with Golub's senior team, read the September issue of Private Debt Investor.